La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.15%285.511.5%$886.84m
MRNAModerna, Inc. 0.48%182.350.0%$766.05m
GILDGilead Sciences, Inc. 1.29%89.031.0%$711.02m
REGNRegeneron Pharmaceuticals, Inc. 0.68%766.392.6%$519.32m
VRTXVertex Pharmaceuticals, Inc. 0.19%321.371.9%$493.66m
BIIBBiogen, Inc. -0.98%298.901.8%$408.64m
ILMNIllumina, Inc. -0.95%218.763.2%$260.35m
BNTXBioNTech SE 0.16%169.740.0%$177.87m
BMRNBioMarin Pharmaceutical, Inc. 2.47%105.564.2%$171.26m
AXSMAxsome Therapeutics, Inc. 6.85%76.901.6%$154.62m
SNSSSunesis Pharmaceuticals, Inc. -5.78%2.120.7%$148.20m
MRTXMirati Therapeutics, Inc. 5.19%96.251.6%$147.31m
HALOHalozyme Therapeutics, Inc. 3.55%59.4418.4%$81.17m
NVAXNovavax, Inc. -1.96%16.5275.3%$77.50m
IMGOImago BioSciences, Inc. 0.03%35.730.0%$57.06m

Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.